--- title: "Cumberland Pharmaceuticals (CPIX) news: buyback" url: "https://aibio.space/companies/cumberland-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CPIX buyback news: Cumberland Pharmaceuticals declares $1.50 special dividend, authorizes $5 million buyback. Cumberland Pharmaceuticals Inc." --- CPIX Cumberland Pharmaceuticals Inc. NASDAQ · United States # Cumberland Pharmaceuticals (CPIX) news CPIX buyback news Financings · 2026-07-13 ## [Cumberland Pharmaceuticals declares $1.50 special dividend, authorizes $5 million buyback](https://aibio.space/news/cumberland-pharmaceuticals-declares-1-50-special-dividend-authorizes-5/) Cumberland will pay a $1.50 special dividend and has authorized up to $5 million of buybacks. The board acted after the Apotex sale produced more net cash than the company had projected. ## Latest Cumberland Pharmaceuticals news 1. 2026-07-01 Mergers [Cumberland Pharmaceuticals closes $100 million asset sale to Apotex affiliates](https://aibio.space/news/cumberland-pharmaceuticals-closes-100-million-asset-sale-apotex/) Cumberland sold six branded products for $100 million in cash and repaid about $5.3 million owed to Pinnacle Bank. It kept ifetroban, whose data so far come from early-stage studies, and its filings do not split out revenue for the products it sold. 2. 2026-07-01 Mergers [Cumberland Pharmaceuticals closes $100 million branded-product deal with Apotex](https://aibio.space/news/cumberland-pharmaceuticals-closes-100-million-branded-product-deal/) Apotex paid $100 million in cash to close the branded-products deal after shareholders approved it. Cumberland now says it will focus on ifetroban, but its release gives no trial figures for any of the programs. 3. 2026-05-15 Mergers [Cumberland Pharmaceuticals files proxy for $100 million asset sale to Apotex](https://aibio.space/news/cumberland-pharmaceuticals-files-proxy-100-million-asset-sale-apotex/) Cumberland would receive $100 million in cash from Apotex and keep its ifetroban programs. Because Tennessee law may treat the sale as a sale of substantially all of its assets, shareholders are asked to approve it. 4. 2025-11-24 Debt Financing [Cumberland Pharmaceuticals extends Pinnacle Bank credit line to October 2027](https://aibio.space/news/cumberland-pharmaceuticals-extends-pinnacle-bank-credit-line-october/) Cumberland's amended Pinnacle Bank line has up to $15 million available, a right to request $10 million more, and a maturity of October 1, 2027. The filing does not say how much is drawn. 5. 2025-02-14 Financings [Cumberland Pharmaceuticals registers up to $10,000,000 in share sales](https://aibio.space/news/cumberland-pharmaceuticals-registers-up-10-000-000-share-sales/) The sales agreement with H.C. Wainwright still limits what it can sell now to $5,800,000, because of a cap tied to its public float. ## Cumberland Pharmaceuticals at a glance - **Ticker**: CPIX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $3.9 million ### Related companies - [Alpha Teknova](https://aibio.space/companies/alpha-teknova/) NASDAQ: TKNO - [Immunic](https://aibio.space/companies/immunic/) NASDAQ: IMUX - [Merck & Company](https://aibio.space/companies/merck-mrk-nyse/) NYSE: MRK - [Perrigo Company](https://aibio.space/companies/perrigo/) NYSE: PRGO - [Oragenics](https://aibio.space/companies/oragenics/) AMEX: OGEN - [Praxis Precision Medicines](https://aibio.space/companies/praxis-precision-medicines/) NASDAQ: PRAX - [Palisade Bio](https://aibio.space/companies/palisade-bio/) NASDAQ: PALI - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AMEX: AIM ### Also on NASDAQ - [SCYNEXIS](https://aibio.space/companies/scynexis/) SCYX - [Compass Therapeutics](https://aibio.space/companies/compass-therapeutics/) CMPX - [Axogen](https://aibio.space/companies/axogen/) AXGN - [Verrica Pharmaceuticals](https://aibio.space/companies/verrica-pharmaceuticals/) VRCA - [Arcturus Therapeutics Holdings](https://aibio.space/companies/arcturus-therapeutics/) ARCT - [Genenta Science S.p.A.](https://aibio.space/companies/genenta-science-s-p-a/) GNTA ## What Cumberland Pharmaceuticals does Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. Its primary target markets are hospital acute care, gastroenterology and oncology. It promotes its approved products through hospital, field and oncology sales divisions in the United States, and works with a network of international partners to register and provide its medicines in their countries. Its FDA-approved brands include Acetadote (acetylcysteine) injection, Caldolor (ibuprofen) injection, Kristalose (lactulose) oral solution, Sancuso (granisetron) transdermal, Vaprisol (conivaptan) injection, Vibativ (telavancin) injection and Tacilia. Its ifetroban product candidate is in Phase II programs for systemic sclerosis and idiopathic pulmonary fibrosis, and the company has announced breakthrough results in a clinical study of ifetroban in cardiomyopathy associated with Duchenne muscular dystrophy. | Product or program | What it is | Stage | |---|---|---| | Acetadote (acetylcysteine) injection | Treatment of acetaminophen poisoning | approved by the FDA | | Caldolor (ibuprofen) injection | Treatment of pain and fever | approved by the FDA | | Vibativ (telavancin) injection | Treatment of serious bacterial infections, including pneumonia and skin infections | approved by the FDA | | Vaprisol (conivaptan) injection | Raises serum sodium levels in hospitalized patients with hyponatremia | approved by the FDA | | Kristalose (lactulose) oral solution | Prescription laxative for the treatment of constipation | approved by the FDA | | Ifetroban | Product candidate studied in systemic sclerosis, pulmonary fibrosis and Duchenne cardiomyopathy | Phase II programs underway | Summarised from the company's [10-K filed Mar 9, 2026](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm). ## Cumberland Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$5.6 million](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/) | [$4.8 million](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/) | | Net income (loss) | [-$2.8 million](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/) | [-$6.5 million](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/) | | Cash from operations | [$4.9 million](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/) | [-$612,186](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/) | | Cash and equivalents | [$11.4 million](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000062/) | [$18.0 million](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Cumberland Pharmaceuticals Does Cumberland Pharmaceuticals have a share buyback? Our latest story on this, dated Jul 13, 2026: "Cumberland Pharmaceuticals declares $1.50 special dividend, authorizes $5 million buyback". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cumberland-pharmaceuticals-declares-1-50-special-dividend-authorizes-5/). What is the ticker symbol of Cumberland Pharmaceuticals? Cumberland Pharmaceuticals Inc. trades under the ticker CPIX on NASDAQ. Where is Cumberland Pharmaceuticals listed? Cumberland Pharmaceuticals Inc. is listed on NASDAQ. What is the SEC CIK of Cumberland Pharmaceuticals? The SEC Central Index Key (CIK) for Cumberland Pharmaceuticals Inc. is 1087294. Its filings are on SEC EDGAR. How many shares does Cumberland Pharmaceuticals have outstanding? 14,983,107 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is Cumberland Pharmaceuticals listed under? Our directory records Cumberland Pharmaceuticals Inc. under United States. What does Cumberland Pharmaceuticals do? Our directory classifies Cumberland Pharmaceuticals Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Cumberland Pharmaceuticals? The ISIN recorded for Cumberland Pharmaceuticals Inc. is US2307701092. Does aibio.space cover Cumberland Pharmaceuticals? aibio.space lists Cumberland Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Cumberland Pharmaceuticals incorporated? SEC records list its state or country of incorporation as TN. What does Cumberland Pharmaceuticals develop? Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. Its primary target markets are hospital acute care, gastroenterology and oncology. What is Acetadote (acetylcysteine) injection from Cumberland Pharmaceuticals? Acetadote (acetylcysteine) injection: Treatment of acetaminophen poisoning Stage: approved by the FDA. What is Caldolor (ibuprofen) injection from Cumberland Pharmaceuticals? Caldolor (ibuprofen) injection: Treatment of pain and fever Stage: approved by the FDA. Is Cumberland Pharmaceuticals profitable? Cumberland Pharmaceuticals Inc. reported a net loss of $2.8 million for the fiscal year ended Dec 31, 2025, and generated $4.9 million of cash from operations, per its annual report to the SEC. How much does Cumberland Pharmaceuticals spend on research and development? $5.6 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Cumberland Pharmaceuticals Members talk about Cumberland Pharmaceuticals (CPIX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Cumberland Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-07-13 Financings Announced a share repurchase program. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000055/cpix-20260713.htm) 2. 2026-07-01 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1087294/000110465926079871/tm2619330d1_ex99-1.htm) 3. 2026-05-15 Mergers Filed documents for a merger or acquisition. SEC Form PREM14A. [Source](https://www.sec.gov/Archives/edgar/data/1087294/000110465926062617/tm2612585-1_prem14a.htm) 4. 2025-02-14 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1087294/000162828025005760/a424b5-stickerprospectussu.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CPIX on TradingView](https://www.tradingview.com/symbols/NASDAQ-CPIX/). ## SEC filings and registration - **SEC name**: Cumberland Pharmaceuticals Inc - **CIK**: 1087294 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CPIX (Nasdaq) - **State or country of incorporation**: TN - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1600 WEST END AVENUE, NASHVILLE,, TN, 37203 - **Phone**: 615-255-0068 - **Shares outstanding**: 14,983,107 as of 2026-08-05 (10-Q filed 2026-08-07) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000064/cpix-20260828.htm) filed 2026-08-28 - [10-Q](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000062/cpix-20260630.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000058/cpix-20260804.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000055/cpix-20260713.htm) filed 2026-07-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1087294/000110465926079871/tm2619330d1_8k.htm) filed 2026-07-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000053/cpix-20260624.htm) filed 2026-06-25 - [10-Q](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000049/cpix-20260331.htm) filed 2026-05-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000046/cpix-20260505.htm) filed 2026-05-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001087294), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Cumberland Pharmaceuticals Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CPIX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Cumberland Pharmaceuticals Inc. - **Ticker**: CPIX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US2307701092 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CPIX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cumberland-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cumberland Pharmaceuticals (CPIX) news: buyback", 2026-10-31, https://aibio.space/companies/cumberland-pharmaceuticals/